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We report here a novel role for Jun dimerization protein-2
(JDP2) as a regulator of the progression of normal cells
through the cell cycle. To determine the role of JDP2
in vivo, we generated Jdp2-knockout (Jdp2KO) mice by
targeting exon-1 to disrupt the site of initiation of
transcription. The epidermal thickening of skin from the
Jdp2KO mice after treatment with 12-O-tetradecanoyl-
phorbol 13-acetate (TPA) proceeded more rapidly than
that of control mice, and more proliferating cells were
found at the epidermis. Fibroblasts derived from embryos
of Jdp2KO mice proliferated faster and formed more
colonies than ﬁbroblasts from wild-type mice. JDP2 was
recruited to the promoter of the gene for cyclin-A2 (ccna2)
at the AP-1 site. Cells lacking Jdp2 had elevated levels of
cyclin-A2 mRNA. Furthermore, reintroduction of JDP2
resulted in the repression of transcription of ccna2 and of
cell-cycle progression. Thus, transcription of the gene for
cyclin-A2 appears to be a direct target of JDP2 in the
suppression of cell proliferation.
Oncogene (2010) 29, 6245–6256; doi:10.1038/onc.2010.355;
published online 30 August 2010
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Introduction
Progression of the cell cycle in mammalian cells is
regulated by the interplay of protein kinase complexes,
known as cyclin-dependent kinases (CDKs). CDKs are
controlled by the levels of expression of their respective
cyclin partners, which act as positive coactivators or as
negative regulators in the case of the so-called CDK
inhibitors (Grana and Reddy, 1995; Sherr and Roberts,
1999; Malumbres and Barbacid, 2009; Satyanarayana
and Kaldis, 2009; Caldon and Musgrove, 2010).
Although cyclin-D–cdk4/6 and cyclin-E–cdk2 control
progression through the G1 phase and cyclin-B–cdc2
appears to be necessary for entry into mitosis (Furuno
et al., 1999), cyclin-A is a rate-limiting component
required for the initiation of DNA synthesis and entry
into mitosis (Pagano et al., 1992; Chaudhry et al., 2004).
There are two subtypes of cyclin-A: cyclin-A2, which is
expressed almost ubiquitously, and cyclin-A1, the
expression of which is restricted to the testis (Sweeney
et al., 1996). In conditional cyclin-A-knockout mice, the
functions of cyclin-A are essential for progression of
hematopoietic cells and embryonic stem cells through
the cell cycle; however, cyclin-A and cyclin-E have
redundant roles in cell proliferation in ﬁbroblasts
(Kalaszczynska et al., 2009).
Jun dimerization protein-2 (JDP2), a member of the
activation protein-1 (AP-1) family, forms homodimers, as
well as heterodimers, with other members of the AP-1
family, such as c-Jun, JunB, JunD and ATF2, and with a
member of the C/EBP family, C/EBPg (Aronheim et al.,
1997; Broder et al., 1998; Jin et al.,2 0 0 1 ) .A s s a y s
involving ectopic expression of JDP2 indicate that it can
block transformation of NIH3T3 cells and of prostate
cancer cell lines (Heinrich et al., 2004). JDP2 also induces
the partial transformation of chick embryonic ﬁbroblasts
(Blazek et al., 2003) and functions as a cell-survival
protein in several cell lines (Piu et al., 2001; Lerdrup et al.,
2005). JDP2 inhibits the differentiation of embryonal
carcinoma F9 cells (Jin et al., 2002) and adipocytes
(Nakade et al., 2007), and even promotes the differentia-
tion of osteoclasts (Kawaide et al., 2003), C2 myoblasts
and rhabdomyosarcoma cells (Ostrovsky et al.,2 0 0 2 ) .
JDP2 most likely participates in the repression of
transcription through multiple mechanisms, which
include DNA-binding competition and inactivation of
the formation of heterodimers with other members
of the AP-1 family (Aronheim et al., 1997), recruitment
of HDAC-3 (Jin et al., 2002), inhibition of histone
acetylation and direct regulation of chromatin assembly
(Jin et al., 2006). However, the details of the physiolo-
gical role of JDP2 in cell fate remain unknown, and the
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proliferation or transformation of cells are yet to be
clariﬁed. Recently, we generated Jdp2-deﬁcient mice
with a deletion in the promoter and non-coding exon-1
region of the Jdp2 locus (Jdp2KO mice) and reported
that ‘knockout’ of Jdp2 affects adipocyte differentiation
(Nakade et al., 2007) and resistance to replicative
senescence (Nakade et al., 2009).
Although our Jdp2KO mice did not show any
apparent abnormalities under standard breeding condi-
tions, we report here that loss of JDP2 results in
accelerated cell cycling by mouse embryonic ﬁbroblasts
(MEFs) and enhances the expressions of cyclin-A2.
Increased expression of cyclin-A2 occurred through loss
of direct binding to the promoter of cyclin-A2 gene at
the AP-1 site. We also observed accelerated cell growth,
which resulted in epidermal thickening in adult Jdp2KO
mice after treatment with 12-O-tetradecanoylphorbol
13-acetate (TPA). Our data indicate that the gene for
cyclin-A2 is one of the targets of JDP2 in the repression
of cell proliferation by JDP2.
Results
Epidermal thickness and scratch-wounding assays
To investigate the functional effect of loss of expression
of the JDP2 gene in vivo, we used the epidermal
thickness assay to compare the back skins from TPA-
treated hairless skins of wild-type (WT) or Jdp2KO
mice. Both WT and Jdp2KO mice have a thin back
epidermis of only 2–3 cells thick (Figure 1). However,
the epidermal thickness of the hairless skins from
Jdp2KO mice increased by 1.4-fold compared with that
of WT mice four days after treatment with TPA (Figures
1A and B). The expression of proliferation cell nuclear
antigen (PCNA) in the epidermis from Jdp2KO mice
was 1.3-fold higher than that in the epidermis of WT
mice (Figures 1B and C). The results of wound-healing
assay in vivo also indicated the higher healing potential
in Jdp2KO mice (Supplementary Figure S1).
Control of the proliferation of Jdp2-deﬁcient cells
We prepared MEFs from Jdp2KO embryos on day 12.5
post coitus. Northern blotting and western blotting of
embryos and MEFs from Jdp2KO mice failed to show
any signals of JDP2 mRNA or protein (Figures 2a and
b). We next examined the proliferation of MEFs using
three different assays, namely, Trypan blue dye exclu-
sion, Alamar Blue assay and colony formation. Jdp2KO
MEFs proliferated more rapidly than WT MEFs when
plated at 5 10
5 cells per 10-cm dish in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) plus 10% fetal calf
serum (FCS) (Trypan blue dye exclusion; Figure 2c).
The results of the cell growth assay with Alamar Blue
dye and colony formation assay also supported this
conclusion (Figures 2d and e). These results indicated
that JDP2 has a crucial role in growth control in vitro
and in vivo.
Absence of a requirement for JDP2 in apoptosis
We found that UV-irradiated MEFs underwent apop-
tosis in a dose-dependent manner at doses of UVC from
20 to 60J/m
2; however, we did not detect any obvious
differences between WT and Jdp2KO MEFs in sub-
sequent Trypan blue dye exclusion assays and assays of
the activities of caspases 3 and 7 (Supplementary
Figures S2A and B). When MEFs were exposed to
UVC at 60 and 600J/m
2, for 2 and 8h, the level of
expression of JDP2 fell signiﬁcantly (Supplementary
Figure S2D). The size of the sub-G1 population of
UV-irradiated MEFs from Jdp2KO mice was identical
to that of MEFs from WT mice (Supplementary Figure
S2C). All reagents of apoptosis inducers increased the
activities of caspases 3 and 7 in a dose-dependent
manner (data not shown); however, no signiﬁcant
differences in respective activities were found between
WT and Jdp2KO MEFs (Supplementary Figure S3)
except after application of cycloheximide. These data
suggested that JDP2 has no signiﬁcant effect on the
apoptotic responses to UV and inducers of cell death in
normal MEFs.
We next performed a cell-cycle re-entry assay,
counting propidium iodide-stained MEFs by ﬂow
cytometry. A representative experiment after 18-h serum
stimulation showed that 28% of Jdp2KO MEFs were in
the S-phase, whereas only 20% of WT MEFs were in the
S-phase (Figure 3a). The number of MEFs derived from
Jdp2KO mice in the S-phase was considerably higher
than that of WT MEFs (1.5-fold; Figure 3b). Prolifera-
tion of Jdp2KO MEFs was accelerated by the enhanced
progression of cells from the G1- or the G0-phase to the
S-phase, and not because of differential activity related
to cell death.
We also examined the incorporation of bromodeoxy-
uridine (BrdU) into MEFs. The percentages of BrdU-
positive cells in the six chambers showed that Jdp2KO
MEFs moved more frequently from a quiescent state to
a proliferative state than did WT MEFs (3.5-fold;
Figures 3c and d).
Regulation of cell-cycle-related genes by JDP2
To examine the role of JDP2 in the cell cycle, we
analyzed the expression of individual cell-cycle-related
genes. MEFs were arrested at the G0/G1-phase by
deprivation of serum for 48h and then re-entry into the
cell cycle was triggered by re-plating in DMEM plus
15% FCS. No notable differences in protein levels, such
as cyclin D1, cyclin D3, cyclin-dependent kinase-4
(cdk4), cdk6 and Rb were detected between WT and
Jdp2KO MEFs (Figure 4a). However, p53 and p21
levels in Jdp2KO MEFs were lower than those in WT
MEFs after induction by serum, suggesting JDP2 might
affect the p53-p21 cascade, which is further discussed in
the section Discussion (Vousden and Prives, 2009).
We next examined global gene expression in Jdp2KO
MEFs using an oligo DNA microarray known as
‘Mouse’ (Agilent Technologies Inc., Santa Clara, CA,
USA) (Supplementary Table 1; the entire data set
from the microarray analysis is available at the Center
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(CIBEX; DDBJ, Mishima, Japan; CIBEX accession,
CBX101)). Higher levels of expression of genes for
cyclin-A2 and cyclin-E2 were detected in Jdp2KO MEFs
as compared with WT MEFs. Conversely, genes for the
CDK inhibitors p21, p16 and p15, but not p27, were
expressed at lower levels in Jdp2KO MEFs than in WT
MEFs. However, the mRNA levels of p53, p107 and RB
were not altered. The expression of genes from families
of apoptosis-related genes and genes for other AP-1 and
C/EBPs did not show any remarkable differences
between Jdp2KO and WT MEFs, except for JDP2 and
C/EBPd. The expression of 21 known genes, including the
Wnt/transforming growth factor-b (TGFb) regulators
Wisp2, Sfrp2 and Ltbp1, was enhanced in Jdp2KO
MEFs as compared with WT MEFs, and the expression
of another 20 known genes, including the Wnt target
gene Lef1 and cAMP/Ca
2þ regulators Cap-1 and Penk-
1, was depressed in Jdp2KO MEFs as compared with
WT MEFs (Supplementary Table 1).
As shown in Figure 4b, the correlation coefﬁcient
with respect to the relative change in levels of mRNAs
between the two assays was higher than 0.8, indicating
that the data from the microarrays were valid.
We examined the levels of the transcripts of representa-
tive genes by real-time PCR and found that the results
were consistent with those in the microarray assay
(Figures 4c and d).
0
2
4
6
8
10
12
0
20
40
60
80
100
E
p
i
d
e
r
m
a
l
 
t
h
i
c
k
n
e
s
s
 
(
μ
m
)
2.73 μm 6.45 μm 6.23 μm 5.87 μm
2.57 μm 2.98 μm
WT
KO
TPA Acetone
WT
KO
9.01 μm 7.46 μm 8.12 μm
P
C
N
A
 
l
a
b
e
l
i
n
g
 
i
n
d
e
x
 
(
%
)
TPA Acetone
WT KO WT KO
WT KO WT KO
TPA
**
*
Acetone
TPA Acetone
3.07 μm 3.21 μm
2.86 μm
Figure 1 Proliferation of epidermal cells of WT and Jdp2KO mice in the TPA-induced epidermal thickness in vivo.( A) WT and
Jdp2KO mice were shaved, painted four times with TPA or acetone and subjected to punch biopsy for pathology examination. Skins
from WT mice and Jdp2KO mice were painted with acetone or 8.1nmol TPA. Ten areas of skin in mid-power ﬁeld were randomly
selected in each section and assayed for their epidermal thickness (n¼3 each group, H&E; scale bar¼100mm). (B) Immunostaining of
the epidermis with antibodies against PCNA. (C) The thickness and PCNA-positive cell number of the epidermis was measured. Data
were sketched in a chart showing the mean±s.e. *Po0.05, **Po0.001. KO, Jdp2-knockout; PCNA, proliferation cell nuclear antigen;
TPA, 12-O-tetradecanoylphorbol 13-acetate; WT, wild type.
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We examined the levels of cyclin-A2 mRNA by real-
time PCR after re-stimulation of MEF by serum. The
expression of cyclin-A2 was enhanced by the addition of
FCS in both WT and Jdp2KO MEF lines (Figure 5a).
However, a more signiﬁcant increase in the expression of
cyclin-A2 was noted in Jdp2KO MEFs than in WT
MEFs after stimulation (41.8-fold; 12h after serum re-
stimulation). In parallel, we also measured the kinetics
of changes in the levels of mRNA for JDP2 and c-fos.
The expression of JDP2 mRNA decreased slightly after
serum stimulation in WT MEFs. By contrast, expression
of c-fos mRNA rose rapidly but transiently within 4h
after the start of stimulation, without any signiﬁcant
difference between the two lines of MEFs. As shown in
Figure 5b, expression of mRNAs for cyclin-A2 and
cyclin-E2 started earlier and were signiﬁcantly higher
and expressions of both genes started earlier in Jdp2KO
MEFs than in WT MEFs after re-addition of serum. By
contrast, expression of p16
Ink4a decreased signiﬁcantly
for the ﬁrst 6h after the start of stimulation with serum
in Jdp2KO MEFs.
Chromatin immunoprecipitation (ChIP) assay
showed that PCR product that corresponded to the
promoter regions of the genes for cyclin-A2 and p16
Ink4a
were detected in sonicated chromatin derived from WT
MEFs but not in that from Jdp2KO MEFs (Figure 5c). In
the case of cyclin-E2, no speciﬁc band was detected. Our
data indicate that the genes for cyclin-A2 and p16
Ink4a are
the most likely targets of JDP2 in the progression of the
cell cycle, even though they showed opposite responses
upon serum stimulation of serum-starved cells.
Promoter analysis of the gene for cyclin-A2
We cloned an 1101-bp fragment of DNA from the
promoter region of the mouse gene for cyclin-A2 and
constructed a series of promoter deletion-luciferase
genes (Figure 6a). We detected 2.5–4.5-fold higher
luciferase activity in Jdp2KO MEFs than in WT MEFs
when we tested this series of deletion constructs (Figures
6b and d). A point mutation at the AP-1 site of this
SacI–XhoI region enhanced luciferase activity in WT
MEFs but not in Jdp2KO MEFs (Figure 6c).
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Figure 2 Proliferative properties of MEFs from WT and Jdp2KO mice. (a) The expression of JDP2 mRNA in embryos and in MEFs
from WT and Jdp2KO mice was analyzed by northern blotting. The blot was re-probed for analysis of GPDH mRNA as loading
control. (b) The expression of JDP2 in MEFs from WT and Jdp2KO mice was examined by western blotting. (c, d) Proliferation of
MEFs from WT and Jdp2KO mice. MEFs were cultured in 10-cm dishes with DMEM plus 10% FCS for 3 days and then re-inoculated
at the same density during 20 passages. Mean cell numbers from four independent plates were determined at each passage.
A representative assay was shown (c; Trypan blue dye-exclusion test). Similar results were obtained in each experiment of three pairs of
independent MEF clones. The number of population doublings (PD) in each passage was calculated as described elsewhere (Polisetty
et al., 2008). Number of cell doubling (NCD)¼log10(N/N0)/log102, where ‘N’ is the ﬁnal density of the cells and ‘N0’ is the initial
seeding density of the cells. In panel d, MEFs were starved in DMEM plus 0.1% FCS for 36h and then re-plated in DMEM plus 15%
FCS and cultured for 5 days. MEFs were counted (six repeats; Alamar Blue assay). *Po0.05; **Po0.001. (e) MEFs from WT and
Jdp2KO mice were plated in gelatin-coated dishes. Colonies (of more than 2mm in diameter) were counted 2 weeks later. DMEM,
Dulbecco’s modiﬁed Eagle’s medium; FCS, fetal calf serum; JDP2, Jun dimerization protein-2; KO, Jdp2-knockout; MEF, murine
embryonic ﬁbroblast; WT, wild type.
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OncogeneTo determine whether JDP2 represses the expression
of the gene for cyclin-A by exploiting its histone
modiﬁcation activity, as described previously (Jin
et al., 2006), we performed ChIP assays and found that
the level of acetylation of histone-H4 in Jdp2KO MEFs
was clearly higher than that in WT MEFs (Supplemen-
tary Figure S4).
Binding of JDP2 to the cyclin-A2 promoter
We performed electrophoretic mobility-shift assays to
verify the DNA-binding activity of JDP2 using DNA
probes that corresponded to the AP-1, the CRE and the
AP-1-like sites (lanes 2–5 in Figure 7). The AP-1 and
CRE probes but not the AP-1-like probe generated
DNA–protein complexes with nuclear extracts (NEs)
from either WT MEFs or Jdp2KO MEFs. The
corresponding competitor AP-1 released [
32P]-AP-1
oligodeoxynucleotide from the DNA–protein complexes
but the mutant competitor mAP-1 did not (lanes 9, 10,
11, 14, 15 versus lanes 12, 13, 16 in Figure 7a). When we
added an antibody speciﬁc for JDP2 to the reaction
mixture with the AP-1 probe, we detected super-shifted
bands in the case of NEs from WT MEFs but not from
Jdp2KO MEFs (lanes 2 and 6 versus lanes 4 and 8 in
Figure 7b). Furthermore, the band in serum-stimulated
WT MEFs was less intense than that from serum-
starved WT MEFs, indicating that addition of serum
suppressed the formation of a protein–DNA complex
that included JDP2 under these conditions. In the case
of the NEs from WT MEFs, the antibodies against
JDP2 and JunD affected the migration and density
of the protein–DNA complexes (lanes 5 and 9 in
Figure 7c); however, antibodies against JunD and
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Figure 3 Proliferation of MEFs from WT and Jdp2KO mice. (a) Serum-starved cells (5 10
5) were cultured in DMEM plus 15% FCS
for 18h, stained with propidium iodide and subjected to FACS analysis to determine the percentage of cells in each phase of the cell
cycle. (b) The percentage of MEFs in the S-phase was determined after re-stimulation in the 15% FCS at 4-h intervals, as in panel a.
(c) MEFs were cultured in chamber slides in DMEM with 15% FCS for 12h and then pulse-labeled with 10 mM BrdU for 3h. Labeled
cells were detected by immunostaining with BrdU-speciﬁc antibodies. Scale bars represent 100mm. (d) Percentages of MEFs that were
stained with BrdU-speciﬁc antibodies. Means of results of three experiments are shown. BrdU, bromodeoxyuridine; DMEM,
Dulbecco’s modiﬁed Eagle’s medium; FACS, ﬂuorescence-activated cell sorting; FCS, fetal calf serum; JDP2, Jun dimerization
protein-2; KO, Jdp2-knockout; MEF, murine embryonic ﬁbroblast; WT, wild type.
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Oncogenec-Jun shifted the DNA–protein complexes in the NEs
from Jdp2KO MEFs (lanes 12 and 14 in Figure 7c). By
contrast, the CRE probe–protein complex was shifted
by the addition of antibodies speciﬁc for JunD but not
by antibodies speciﬁc for JDP2 (lane 9 in Figure 7d),
indicating that the CRE site ‘preferred’ members of the
AP-1 family other than JDP2. These data strongly
suggest that JDP2 binds to the AP-1 site of the cyclin-A2
gene promoter.
Elevated levels of cyclin/cdk complex and cdk activity
in Jdp2KO cells
The level of cyclin-A2 was fourfold higher in Jdp2KO
MEFs than in WT MEFs at 8h after stimulation with
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Figure 4 Gene expression in WT and Jdp2KO MEFs as determined by western blotting, microarray analysis and real-time PCR. (a)
Western blots of cell-cycle-related proteins in MEFs from WT and Jdp2KO mice. MEFs were synchronized by serum starvation for
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(b) Summary of the microarray data obtained with mRNA from WT and Jdp2KO MEFs. (c) Validation of hybridization intensities.
The correction coefﬁcient with respect to relative changes in mRNA levels in two assays was higher than 0.8, indicating that the
microarray data are valid. (d) Analysis by quantitative PCR of the expression of representative genes using mRNA from WT MEFs
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MEF was taken as 100. FCS, fetal calf serum; KO, Jdp2-knockout; MEF, murine embryonic ﬁbroblast; WT, wild type.
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Oncogeneserum (Figure 8a). We also found that no signiﬁcant
increases of cyclin-E2, cdk1 and cyclin-B1 proteins
(Figure 8a, data not shown). We immunoprecipitated
cdk2 from equal amounts of cell lysates prepared from
WT and Jdp2KO MEFs 0, 8, 16 and 20h after re-
addition of FCS (Figure 8b). Immunoblotting of the
immuprecipitates and/or cell lysates with antibodies
speciﬁc for cyclin-A2, cyclin-E2, cdk2 and b-actin as a
loading control showed that the amounts of cdk2-
associated cyclin-A and of cdk2-associated cyclin-E2
were increased by serum stimulation (two- and ﬁvefold,
and six- and twofold, at 16 and 20h, respectively), even
though the level of cdk2 was almost constant.
In an attempt to measure the levels of cyclin-
associated kinases, we prepared lysates from WT and
Jdp2KO MEFs and subjected them to immunoprecipi-
tation with antibodies against cyclin-A2 and cyclin-E2.
We found that immunoprecipitates of cyclin-A2 and
cyclin-E2 from Jdp2KO MEFs had 8- and 3-fold higher
kinase activity, respectively, than those from WT MEFs
(on the basis of radioactivity; Figure 8c). The increased
kinase activity of cyclin-E2 was found 12 and 24h after
serum stimulation, and that of cyclin-A2 was detected
24h after serum stimulation.
Repression of cell growth and the reporter activity of the
cyclin-A2 promoter
We examined the effects of JDP2 on the proliferation of
MEFs by overexpressing JDP2 in WT MEFs and re-
expressing JDP2 in Jdp2KO MEFs. First, we introduced
a pJDP2 vector into WT and Jdp2KO MEFs (two- to
threefold increase of JDP2 mRNA than that of WT
MEFs). Introduction of pJDP2 suppressed cell growth
in both lines of MEFs (Figure 9a). We used the cyclin-
A2 promoter–reporter construct pA2M and its AP-1
mutant pA2mAP-1 to examine the effect of re-expres-
sion of JDP2 in Jdp2KO MEFs. Transfection with
pJDP2 signiﬁcantly reduced the reporter luciferase
activity in pA2M, but not in the mutant reporter
pA2mAP1 (Figure 9b). These data suggested, yet again,
that JDP2 represses the activity of the cyclin-A2
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Figure 5 Kinetics of expression of cell-cycle-related genes in WT and Jdp2KO MEFs. (a) Relative levels of expression of genes for
cyclin-A2, JDP2 and c-fos during cell cycling. Serum-starved MEFs from Jdp2KO (KO; black squares) and WT (black circles) mice
were re-stimulated with serum for 24h. The relative levels of respective mRNAs, normalized by reference to GPDH mRNA, were
compared at the indicated time points. (b) Western blots of products of cell-cycle-related genes in lysates of MEFs from Jdp2KO and
WT mice at the indicated time points. GPDH was used as control. (c) ChIP assays with JDP2-speciﬁc antibodies of lysates of Jdp2KO
and WT MEFs with and without stimulation with serum. DNA fragments of genes for cyclin-A2, p16
Ink4a and cyclin-E2 were detected
by PCR with respective primers (Supplementary Table 2). ChIP, chromatin immunoprecipitation; JDP2, Jun dimerization protein-2;
KO, Jdp2-knockout; MEF, murine embryonic ﬁbroblast; WT, wild type.
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Oncogenepromoter, in a manner dependent speciﬁcally on the
AP-1 site.
The infection with adenovirus JDP2 (Ad-JDP2)
signiﬁcantly suppressed cell growth in both WT and
Jdp2KO MEFs, acting in a dose-dependent manner,
even at a multiplicity of infection of 1 (Ad-JDP2
increased the expression of JDP2 by 50–100-fold;
Nakade et al., 2009). Infection with the JDP2-expressing
virus almost halved the number of WT and Jdp2KO
MEFs by day 5 (Figure 9c). However, expression of
cyclin-A2 was depressed in Jdp2KO MEFs (Figure 9d).
In WT MEFs, two different JDP2–siRNA constructs
reduced the expression level of JDP2 by as much as 50%
(Figure 9f). These small interfering RNAs (siRNAs)
accelerated the proliferation of WT MEFs but not of
Jdp2KO MEFs (Figure 9e). Furthermore, treatment
of WT MEFs with JDP2–siRNA increased the level of
cyclin-A2 mRNA but reduced the level of cyclin-A2
mRNA in Jdp2KO MEFs (Figure 9f). These data
strongly suggest that JDP2 represses the progression of
the cell cycle through expression of cyclin-A2, thereby
inhibiting the proliferation of MEFs at least partially.
Discussion
In this study, we show that loss of JDP2 accelerates cell-
cycle progression with higher cyclin-associated cdk
kinase activities in MEFs and cyclin-A2 is one of the
molecular targets of JDP2. Thickening of epidermis
after treatment with TPA showed the proliferation
inhibition of JDP2 in mice skin derived from Jdp2KO
and WT mice in vivo. Other assays in vitro, including
population doubling, cell cycle and BrdU-incorpora-
tion, showed the elevated proliferative potential of
Jdp2KO MEFs as compared with WT MEFs.
To identify the molecular targets of JDP2 on cell
proliferation, we performed a microarray-quantitative
PCR analysis and found genes encoding cyclin-A2,
p16
Ink4a and cyclin-E2 are the potential targets of JDP2.
So far, only ﬁve JDP2 targets were identiﬁed, namely
c-Jun, ATF-2, C/EBPd, ATF3 and CHOP10 (Aronheim
et al., 1997; Jin et al., 2001; Nakade et al., 2007;
Cherasse et al., 2008; Weidenfeld-Baranboim et al.,
2009). Here we found that JDP2 was recruited to the
promoter of the gene for cyclin-A2 at the AP-1 site. A
gel-shift assay and site-directed mutagenesis of the
promoter also showed that the AP-1 site is crucial for
JDP2-mediated repression of the cyclin-A2 promoter,
suggesting that JDP2 is the major component in the
regulation of the cyclin-A2 promoter. However, the
endogenous partner with JDP2 to form heterodimer
in vivo has not been identiﬁed yet.
A number of studies suggest that JDP2 has a dual role
with pro- or anti-oncogenic properties in malignant
transformation. JDP2 was found to inhibit cell-cycle
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Figure 6 JDP2 negatively regulates the expression of the gene for cyclin-A2. (a) Schematic representation of the promoter of the
cyclin-A2 gene (nt  944 to þ157) fused with a gene for the luciferase. The series of deletion mutants of cyclin-A2-luciferase are
described in the text. The AP-1-like motif, AP-1 motif and CRE are indicated by a white box, a gray box and a black box, respectively.
Point mutations in each motif are also indicated. (b) Reporter activities of cyclin-A2-reporter deletion constructs pA2-L, pA2-M and
pA2-N. A 1-mg weight of cyclin-A2 promoter-luciferase reporter plasmid and 200ng of pSV-luc were used for transfection of 5 10
4
Jdp2KO MEFs. Six hours after transfection, MEFs were washed, incubated for another 48h and assayed. *Po0.001. (c) Luciferase
activities of the point mutants of the cyclin-A2 promoter-luciferase constructs were determined as in panel b.( d) The pSV-luc plasmid
was used as control for transfections in comparisons of Renilla luciferase activities of MEFs from Jdp2KO and WT mice. AP,
activation protein; JDP2, Jun dimerization protein-2; KO, Jdp2-knockout; MEF, murine embryonic ﬁbroblast.
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Oncogeneprogression (Ostrovsky et al., 2002), Ras-dependent cell
transformation and tumor formation in xenografts
(Heinrich et al., 2004). Conversely, overexpression of
JDP2 in chicken embryo ﬁbroblasts imparts a partial
oncogenic phenotype (Blazek et al., 2003). Furthermore,
viral integration sites were identiﬁed within the genome
of JDP2 resulting in T-cell lymphoma (Hwang et al.,
2002; Rasmussen et al., 2005, 2009; Stewart et al., 2007).
Recent publication showed that JDP2 potentiates the
chemical carcinogenesis of liver cancer (Bitton-Worms
et al., 2010). JDP2 acts at the promotion stage in which
full blown inﬂammation is evident. Furthermore, multi-
ple members of the bZIP family are highly expressed at
this stage, including CHOP10. Heterodimerization
between CHOP10 with either ATF3 or overexpressed
JDP2 transgene may result in the transcriptional
activation (Weidenfeld-Baranboim et al., 2008) of
otherwise suppressed JDP2 target genes involved in
cell-cycle progression such as cyclin-A2, cyclin-E2 or
p16
Ink4a, which were identiﬁed in this report. These data
indicate that JDP2 acts as a transcriptional activator or
a repressor depending on the bZIP protein at each stage
of cancer progression with which it is associated.
However, the role of JDP2 in cancer progression
mediated through regulation of cyclin-A2 transcription
has not been determined yet; further investigations are
necessary to clarify the JDP2 partner to regulate cell-
cycle progression in response to various signals.
We show here that transcriptional regulation is the
major mechanism of the JDP2-mediated expression of
the cyclin-A2 promoter. Other possible regulations
described below cannot be ruled out. First JDP2-
mediated inhibitions of histone acetylation at H3 and
H4 (Jin et al., 2006; Nakade et al., 2007) and histone
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NE:
Comp.
Probe: FCS -
Anti-JDP2:
NE:
FCS +
Cold CRE
←B1
Free
B2 → ←B3
←B4
←B2
← B1
Free
← B3
← B4
← B2
← X 
← *
Free
←B1
←B2
← X 
B1 →
←B1
←B3
←B4
←B2
← X 
← * ← *
P
r
o
b
e
 
o
n
l
y
A
n
t
i
-
c
-
J
u
n
N
o
n
e
A
n
t
i
-
E
2
F
1
A
n
t
i
-
A
T
F
2
A
n
t
i
-
c
-
F
o
s
A
n
t
i
-
J
u
n
B
A
n
t
i
-
J
u
n
D
A
n
t
i
-
j
J
D
P
2
#
1
7
6
P
r
o
b
e
 
o
n
l
y
A
n
t
i
-
c
-
J
u
n
N
o
n
e
A
n
t
i
-
E
2
F
1
A
n
t
i
-
A
T
F
2
A
n
t
i
-
c
-
F
o
s
A
n
t
i
-
J
u
n
B
A
n
t
i
-
J
u
n
D
A
n
t
i
-
j
J
D
P
2
#
1
7
6
WT NE WT NE
A
n
t
i
-
j
J
D
P
2
#
2
4
9
A
n
t
i
-
j
J
D
P
2
#
1
7
6
A
n
t
i
-
c
-
J
u
n
A
n
t
i
-
A
T
F
2
A
n
t
i
-
c
-
F
o
s
A
n
t
i
-
J
u
n
B
A
n
t
i
-
J
u
n
D
K W K W K W K W B
AP1 mAP1 AP1 mAP1
-- -
- - - - - - -
16 15 14 12 13 11 10 9 8
B
7 6 5 4 3 2 1
K K W W K K W W
+ - + - + - + -
12345678
KO NE
1 23456789 123456789 1 0 1 1 10 11 12 13 14 15 16 17 18
* *
Figure 7 Electrophoretic mobility-shift assays with NEs with MEFs from WT and Jdp2KO mice. (a) NEs from Jdp2KO MEFs
(indicated as K), WT MEFs (indicated as W) and bovine serum albumin (BSA; indicated as B were incubated with probes
corresponding to the CRE (lanes 1–3), AP1-like sequence (AP1L; lanes 4 and 5), the AP-1 point mutant (mAP1, lanes 6 and 7)
and AP-1 (lanes 8–16) in the presence of 1 and 2pmol of unlabeled mAP1 oligodeoxynucleotide (lanes 12 and 13) or AP-1
oligodeoxynucleotide (lanes 10 and 11) as a competitor. The positions of shifted bands (B1–B4) and free DNA probes (Free) are
indicated. (b) Super-shifting electrophoretic mobility-shift assay using NEs from serum-starved MEFs (FCS ) or 15% serum-induced
MEFs (FCSþ) and the DNA probe that corresponded to AP-1. NEs from WT MEFs (W) and Jdp2KO MEFs (K) were incubated
without (odd lanes) or with (even lanes) antibodies speciﬁc for JDP2. ‘*’ indicates the super-shifted bands and X indicates aggregated
DNA–protein complexes that remained in the wells of the gel. B1–B4 and Free indicate protein–DNA complexes and free DNA
probes. (c) Competition and super-shifting assays with the AP-1 DNA probe. Reaction mixtures containing NEs from WT MEFs
(lanes 1–9) and Jdp2KO MEFs (lanes 10–18) were prepared with antibodies speciﬁc for c-Jun, JunB, JunD, c-Fos, ATF-2, E2F1 and
JDP2 (lanes 1–18), as indicated. ‘*’ indicates super-shifted bands of antibody–DNA–protein complexes. B1–B4 and Free indicate
DNA–protein complexes and the unbound AP-1 probe. (d) Competition and super-shifting assays using NEs of WT MEFs and the
CRE DNA probe. Reaction mixtures containing NEs from WT MEFs were prepared without (lane 1) and with 0.1, 1 and 10pmol of
unlabeled (cold) CRE probe (lanes 2–4) and antibodies speciﬁc for JDP2, pJDP2, c-Jun, JunB, JunD, c-Fos and ATF-2 (lanes 5–11), as
indicated. B2 indicates super-shifted bands of antibody–DNA–protein complexes. B1 and Free indicate DNA–protein complexes
and the unbound CRE probe. AP, activation protein; FCS, fetal calf serum; JDP2, Jun dimerization protein-2; KO, Jdp2-knockout;
MEF, murine embryonic ﬁbroblast; NE, nuclear extract; WT, wild type.
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Oncogenemethylation at H3K27 at p16
Ink4a locus (Nakade et al.,
2009) are possible. Second, the stability of cyclin-A2
might be controlled by JDP2 (Mateo et al., 2009; data
not shown). In fact, we found that JDP2 colocalized
with cyclin-A in the nucleus (Supplementary Figure S6).
In the case of cyclin-E2 the mRNA and protein levels
after serum induction were not coincident each other
and, however, the cdk2–cyclin-E2 complex showed
slightly higher cyclin-associated cdk kinase activity in
Jdp2KO MEFs as compared with that in WT MEFs.
The speciﬁc recruitment of JDP2 to the promoter of
cyclin-E2 was not detected and no AP-1/CRE elements
were found in the promoter of the cyclin-E2 gene. Thus,
regulation of cyclin-E2 by JDP2 might not be direct
transcriptional regulation by JDP2. Another indirect
regulation like JDP2-induced p16
Ink4a-Rb-E2F regula-
tion of cyclin-E2 gene might be possible (Nakade et al.,
2009; Polager and Ginsberg, 2009).
The increase in the protein levels of p53 and p21
proteins was less signiﬁcant in Jdp2KO MEFs after
stimulation by serum as compared with that in WT
MEFs. We generated p53-knockdown MEFs by using a
short-hairpin RNA against p53 (shp53) and introduced
lentivirus vector-encoded JDP2 (Supplementary Figure
S5A). In MEFs in which p53 was downregulated
completely, JDP2 still inhibited cell proliferation sig-
niﬁcantly (4P¼0.0075; Supplementary Figures S5B
and S5C). In addition, expression of p53 mRNA was
increased by introducing JDP2 the level of which is
comparable with the results in Figure 4a. These
observations indicate that JDP2 may inhibit cell
proliferation in p53-dependent and p53-independent
manners, in the latter case, at least partially, by
suppression of cyclin-A2 gene.
In summary, our data indicate that JDP2 has a crucial
role in the suppression of cyclin-A2 expression, with
subsequent inhibition of cyclin-associated cdk kinase
activity, and in the suppression of cell proliferation. This
hypothesis is also supported by overexpression of JDP2
encoded by a recombinant adenovirus and by gene
suppression experiments with siRNA. The expression of
cyclin-A2 is controlled at the transcription level by
JDP2. It is clear that JDP2 interferes with progression
of the cell cycle at least partially by downregulation of
cyclin-A2 but not apoptosis. The control of cell cycle
by JDP2 may then lead to the commitments of cell
differentiation, cellular senescence or cell fate determi-
nation possibly through the signal cascades of RB-E2F
or p53-p21 or Wnt/TGFb as indicated by the results of
microarray and qPCR.
Materials and methods
Cell culture
MEFs were prepared from embryos at embryonic day 12.5
(E12.5) with a mixed genetic background of B6 and 129
as described previously (Nakade et al., 2007). For serum
starvation experiments, MEFs were incubated in DMEM
containing 0.1% FCS for 48h, at conﬂuence; then they were
re-plated in DMEM that contained 15% FCS.
TPA-induced epidermal thickening assay
The assay for epidermal thickening was measured as described
previously with a slight modiﬁcation (Nakamura et al., 1998).
Brieﬂy, the dorsal skin of each mouse (six pairs of WT and
Jdp2KO) was shaved before treatment with TPA. TPA or
acetone as solvent control was administered four times to each
animal at an interval of 24h (8.1nmol in 100ml acetone;
Sigma-Aldrich Co., St Louis, MO, USA). Mouse skin was
obtained 1h after the fourth application of TPA or acetone.
Tissues were frozen and sectioned at 5ı`m thickness. The
epidermal thickness of the skin was measured at 10 randomly
selected sites using an Olympus microscope (Olympus, Tokyo,
Japan). The vertical thickness of the epidermis was deﬁned as
the distance from the stratum basal to the stratum corneum.
After incubation overnight at room temperature with or
without mouse monoclonal antibody against PCNA (PC10;
Abcom, Cambridge, MA, USA), slides were incubated with
goat anti-mouse IgG 1h at room temperature. PCNA labeling
index was calculated by immunoreactive nuclei per total nuclei
in epidermis.
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Figure 8 Enhanced cyclin–cdk activity in Jdp2KO MEFs. Cell
growth was synchronized and cells were stimulated as described in
the text. (a) Western blots (Wes) of cyclin-A2, cyclin-E2, cdk1 and b-
actin in whole-cell lysates (left panel) and NEs (right panel).
(b) Levels of the cdk-associated cyclin family. Whole-cell extracts
from WT and Jdp2KO MEFs were immunoprecipitated (IP) with
antibodies speciﬁc for cdk2 and then immunoprecipitates were
subjected to sodium dodecyl sulfate-PAGE (10% acrylamide) and
blotted with antibodies against cyclin-A2, cyclin-E2 and cdk2.
Control of western blot using b-actin is indicated (lower panel).
(c) Induction of cyclin–cdk phosphorylation of histone-H1. Immu-
noprecipitates containing the complexes with cyclin-A2 and cyclin-E2
were isolated from whole-cell extracts (400mg total protein) using
cyclin-A2- and cyclin-E2-speciﬁc antibodies and histone-H1-phos-
phorylating activity was determined in vitro as described in the text.
cdk, cyclin-dependent kinase; KO, Jdp2-knockout; MEF, murine
embryonic ﬁbroblast; NE, nuclear extract; WT, wild type.
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Cyclin-A2 promoter-reporter DNAs were transfected into WT
and Jdp2KO MEFs with or without pcDNA3-JDP2 or
pcDNA3 empty vector as 1mg of total DNA per well of a
24-well plate (5 10
4 cells/well) using 2ml of Lipofectamine-
2000 reagent (Invitrogen, Paisley, UK). A series of JDP2
promoter-reporters were transfected as described elsewhere
(Jin et al., 2002; Nakade et al., 2007).
Assay of cyclin-associated kinase activity
We immunoprecipitated total cellular proteins with antibodies
against cyclins as indicated and using protein-A- and protein-
G-Sepharose beads. Beads with bound immune complexes
were mixed with [
32P]-ATP and histone H1 peptide substrate
(cat. no. 14–155; Upstate Biotechnology Inc., Charlottesville,
VA, USA) in a kinase assay buffer (50mM HEPES (pH 7.0),
10mM MgCl2, and 1mM dithiothreitol) for 30min at 301C.
Reaction products were resolved by sodium dodecyl sulfate-
PAGE (12% polyacrylamide) and phosphorylated histone H1
peptide was detected by autoradiography.
Analysis of data
Results are expressed as the means±s.d. of the results for
each set of replicates. Statistical comparison of single
parameters between two groups was performed by paired
Student’s t-test. P-values less than 0.05 or 0.01 were considered
signiﬁcant.
Plasmid constructions, generation and characterization of
JDP2-deﬁcient mice, skin wound healing, cell cycle, isolation
of RNA, microarrays and real-time quantitative reverse
transcription–PCR, recombinant virus infection and siRNA
transfection, cell proliferation and apoptosis, electrophoretic
mobility-shift assays, immunoprecipitation-western blotting,
ChIP assay and immunoﬂuorescence are described in the
Supplementary Information.
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Figure 9 Effects of ectopic JDP2 and siRNA speciﬁc for JDP2 on
proliferation and expression of cyclin-A2. (a) Reduced prolifera-
tion of WT and Jdp2KO MEFs upon expression of the JDP2
expression vector. 2 10
4 WT and Jdp2KO MEFs were transfected
with 600ng of pcDNA4-JDP2 or pcDNA and cells were counted 3
days later by the Alamar Blue method. The relative cell number
on day 0 is given as one. The means of the results of three
experiments±s.d. are shown. (b) Depressed cyclin-A2 reporter
activity upon introduction of the JDP2 expression vector. We
introduced 600ng of pJDP2 or pcDNA4, and 400ng of pA2M or
pA2mAP1 into 5 10
4 Jdp2KO MEFs, incubated the cells for 30h
and then measured luciferase activities. (c) Depressed proliferation
of MEFs upon infection with recombinant adenovirus encoding
JDP2 (Adeno-JDP2). WT and Jdp2KO MEFs (2 10
4) were
infected with Ad-JDP2 or b-galactosidase-encoding cDNA (Ad-
cont) at a multiplicity of infection of 1 and 10. Cells growth was
counted 5 days later. (d) Depressed expression of mRNA for cyclin-
A2 in Jdp2KO MEFs infected with Ad-JDP2. The culture and
infection of cells are described in the legend to panel c. The
expression of mRNA speciﬁc for cyclin-A2 was quantitated by real-
time PCR as described in the legend to Figure 7a. (e, f) Effects of
siRNA speciﬁc for JDP2 on cell proliferation and expression of
cyclin-A2. WT MEFs (5 10
5 cells) were transfected with 30pmol
of siRNA speciﬁc for JDP2 (JDP2si#1 and #2) and non-speciﬁc
double-stranded RNA (CONTsi). Three days after transfection,
cells were harvested and counted (e), and total RNA was subjected
to real-time PCR using primers speciﬁc for JDP2 or cyclin-A2 (f).
The levels of expression were normalized by reference to that of
GPDH mRNA. Data are shown as percentages, relative to results
for WT MEFs as negative control. JDP2, Jun dimerization protein-
2; KO, Jdp2-knockout; MEF, murine embryonic ﬁbroblast;
siRNA, small interfering RNA; WT, wild type.
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